Merck Millipore announces 2013 price hike

- Last updated on GMT

Related tags: Merck millipore, Cost

Merck Millipore to raise prices on costs
Merck Millipore has announced plans to increase what it charges for chemical and biopharmaceutical processing solutions, citing rising costs.

The Germany-based firm - which operates as EMD Millipore in the US - said that it would increase prices by between four and six per cent as of January 1 next year, explaining that the move was driven by recent and anticipated cost increases, macroeconomic trends and inflation among other considerations.

Andrew Bulpin, company head of process solutions, said: "The 2013 price increase for process solutions products reflects the impact of higher costs, associated with raw materials, energy and labour, and increased regulatory demands on the pharmaceutical and biopharmaceutical industry.

"These nominal price modifications will help us continue delivering the high level of quality products, pharmaceutical ingredients and services our customers expect, thereby ensuring patient safety and increasing speed to market​."

Merck Millipore said that the price increases will differ by product lines depending on the specific impact of cost drivers and market dynamics.

Expansion

The price hike follows a period of expansion for Merck Millipore's process solutions business, beginning in March when the firm partnered with Canada's Center for the Commercialisation of Regenerative Medicen​ on a bioreactor optimisation project.

Since then the firm has expanded its technology offering​, partnered with two UK firms on vaccine development​ and launched a new media for CHO cells​.

More recently​ Merck Millipore established a facility in Martillac, France where it will offer both process development services and contract manufacturing. 

Whether the additional investment Merck made in these projects was a factor in driving up its costs is unclear, but the success of these expansion efforts combined with the price hikes could result in a considerable boost for the firm next year.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers